Ponezumab in mild‐to‐moderate Alzheimer's disease: Randomized phase II PET‐PIB study
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Introduction: The safety, pharmacokinetics, and effect on peripheral and central amyloid β (Aβ) of multiple doses of ponezumab, an anti‐Aβ monoclonal antibody, were characterized in subjects with mild‐to‐moderate Alzheimer's disease treated for 1 year. Methods: Subjects were aged ≥50 years with Mini–Mental State Examination scores 16 to 26. Cohort Q was randomized to ponezumab 10 mg/kg ( n = 12) or placebo ( n = 6) quarterly. Cohort M was randomized to a loading dose of ponezumab 10 mg/kg or placebo, followed by monthly ponezumab 7.5 mg/kg ( n = 12) or placebo ( n = 6), respectively. Results: Ponezumab was generally well tolerated. Plasma concentrations increased dose dependently, but cerebrospinal fluid (CSF) penetration was low. Plasma Aβ increased dose dependently with ponezumab, but CSF biomarkers, brain amyloid burden, cognition, and function were not affected. Conclusions: Both ponezumab dosing schedules were generally safe and well tolerated but did not alter CSF biomarkers, brain amyloid burden, or clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“A recent review of the amyloid hypothesis by Selkoe [26] suggests that Ab dyshomeostasis has emerged as the most extensively validated and compelling therapeutic target.”
BackgroundThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“Aducanumab, which has selectivity for fibrillary amyloid has demonstrated convincing phase II results in support of the amyloid hypothesis [28].”
BackgroundVillemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 2×
“In studies of bapineuzumab, PIB showed significant differences in amyloid burden between the treatment and control groups; there were also significant differences in CSF p-tau concentrations between the two groups among patients who were carriers of the APOE ε4 allele [4].”
BackgroundPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 3×
“In patients with mild-to-moderate AD, bapineuzumab did not improve clinical outcomes [4] and solanezumab did not significantly improve cognitive or functional ability [5].”
BackgroundDeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1893 · Cited by 370 · cited 1×
“However, secondary analyses suggested that in patients with mild AD, solanezumab may have slowed cognitive worsening [7], and a delayed start design in an extension arm indicated a potential modifying effect on underlying disease progression [8].”
BackgroundSolanezumab: too late in mild Alzheimer's disease?
Neurology, T. L. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30395-7 · Cited by 58
Cited by
Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306
BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease
Moussa‐Pacha, N. M., Abdin, S. M., Omar, H. A., Alniss, H., & Al‐Tel, T. H. (2020) · Medicinal Research Reviews · doi:10.1002/med.21622 · Cited by 274
Barakos, J., Purcell, D., Suhy, J., Chalkias, S., Burkett, P., Grassi, C. M., Castrillo-Viguera, C., Rubino, I., & Vijverberg, E. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.21 · Cited by 165
“By contrast, treatment with mAbs that target the mid-domain or C-terminus of Aβ, such as solanezumab or ponezumab, has been associated with a lower incidence of ARIA (13, 32).”
BackgroundDrug development for alzheimer’s disease: Microglia induced neuroinflammation as a target
Dong, Y., Li, X., Cheng, J., & Hou, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030558 · Cited by 136
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119
“A number of antibodies that have advanced to phase 3 studies in symptomatic AD have not shown evidence for efficacy either with respect to marked lowering of the PET ligand signal, or any significant clinical impact (ponezumab [44], solanezumab [39, 45–47], bapineuzumab [48], crenezumab [49]).”
BackgroundEbell, M. H., Barry, H. C., Baduni, K., & Grasso, G. (2024) · The Annals of Family Medicine · doi:10.1370/afm.3050 · Cited by 100
Qiao, Y., Gu, J., Yu, M., Chi, Y., & Ma, Y. (2024) · CNS Drugs · doi:10.1007/s40263-024-01067-2 · Cited by 38
Metadata
- Authors
- Landen, J. W., Andreasen, N., Cronenberger, C. L., Schwartz, P. F., Börjesson‐Hanson, A., Östlund, H., Sattler, C. A., Binneman, B., & Bednar, M. M.
- Venue
- Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Publisher
- Wiley
- Published
- 2017-06-08
- Volume
- 3
- Issue
- 3
- Pages
- 393-401
- ISSN
- 2352-8737 (ISSN-L)
- OpenAlex
- W2623803671
- Cited by
- 69
- References
- 9
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.